Related Experiment Videos
Natalizumab. Elan/Biogen.
1PharmaMar USA, 320 Putnam Avenue, Cambridge, MA 02139, USA. melices@pharmamarusa.com
Current Opinion in Investigational Drugs (London, England : 2000)
|February 5, 2004
Summary
Natalizumab, a monoclonal antibody targeting alpha 4 beta 1 integrin (VLA-4), is being developed for Crohn's disease and multiple sclerosis. Clinical trials are progressing, with Phase III studies initiated by late 2002.
Area of Science:
- Immunology
- Neuroscience
- Gastroenterology
Background:
- Natalizumab is a humanized monoclonal antibody.
- It targets alpha 4 beta 1 integrin (VLA-4).
- It is under development for Crohn's disease and multiple sclerosis.
Purpose of the Study:
- To evaluate Natalizumab for Crohn's disease treatment.
- To assess Natalizumab for multiple sclerosis treatment.
Main Methods:
- Phase II trials completed for both indications.
- Phase III trials initiated by December 2002.
Main Results:
- Data from Phase II trials informed Phase III initiation.
- Further results are pending from ongoing trials.
Conclusions:
- Natalizumab shows promise for treating immune-mediated diseases.
- Ongoing trials will determine efficacy and safety in Crohn's disease and multiple sclerosis.